Steve Greene
@SJGreene_md
Cardiologist at @DukeHeartCenter & @DCRINews | Podcast: #DontMissABeat | Views & tweets are my own
ID:950586157364064256
https://medicine.duke.edu/faculty/stephen-greene-md 09-01-2018 04:32:55
4,0K Tweets
2,8K Followers
153 Following
Learn about DCRM 2.0 - Multi-Specialty Practice Recommendations for DM, Cardiorenal, & Metabolic Disease. Simultaneously presented at #8HID and published at the Journal Metabolism.
#HID24 #CME #CKM #8thHeartinDiabetes #MedEd #HID2024 Steve Greene Erin D. Michos, M.D. Javed Butler
Learn about DCRM 2.0 - Multi-Specialty Practice Recommendations for DM, Cardiorenal, & Metabolic Disease. Simultaneously presented at #8HID and published at the Journal Metabolism.
#HID24 #CME #CKM #8thHeartinDiabetes #MedEd #HID2024 Steve Greene Erin D. Michos, M.D. Javed Butler
Terrific work led by Duke Cardiology Fellows Mark Kittipibul MD
Many π₯ and #HF patients continue to struggle w readmissions.
Across #RCTs , #SGLT2i significantly reduce both HF and **all-cause** hospitalization, regardless of EF
πjacc.org/doi/10.1016/j.β¦
Duke Clinical Research Institute Muthu Vaduganathan
#HFupdate Day 1! We start off the day with a Call to Action from HeartLife Foundation announcing a Bill has been tabled to address #heartfailure care in π¨π¦. πMarc Bains πππππππππ ππππ, ππ.π πβοΈπ»π§‘ for your leadership Senator Yonah Martin + Senator F. Gigi Osler for your support. Much work to do #advocacy
Steve Greene speaks at #HFUpdate on implementation of #GDMTworks across the continuum of ejection fraction. CHFS HeartLife Foundation Muthu Vaduganathan Anu Lala-Trindade Dr. Martha Gulati β₯οΈπ«β€οΈβπ©Ήπ¨π¦ Nosheen Reza, MD Emer Joyce Yas Moayedi Mena g
Getting ready to for great opening session CHFS meeting! Time to talk #GDMTworks
Shelley Zieroth Justin Ezekowitz Duke Clinical Research Institute
Effects of semaglutide on CV outcomes in FLOW presented by Kenneth Mahaffey
18% reduction in MACE
20% reduction in all cause mortality
NNT 39 to prevent one death over 3 years
#erakidney ERA - European Renal Association
Do not miss the #ESC_HFA scientific statement on how to tackle clinical inertia in #HF . Pragmatic suggestions on implementing GDMT in clinical practice onlinelibrary.wiley.com/doi/full/10.10β¦ European Society of Cardiology Journals EJHF Editor-in-Chief HFAPresident Henry Han Steve Greene
Karolinska Institutet Karolinska Univ.sjuk Gregg Fonarow MD
Fantastic Duke Cardiology grands rounds by future EP Ilya Shadrin, MD/PhD on his research and Insights into Conduction System Pacing! Duke Heart Dan Friedman Jonathan Piccini, MD, MHS Camille Frazier-Mills, MD MHS Larry R. Jackson II, MD, MHSc Kevin L. Thomas
Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure:
A pre-specified analysis from the from the SELECT trial
The demonstrated benefits of semaglutide were not different in HFpEF compared to HFrEE
Muthu Vaduganathan
The Inflation Reduction Act and Access to Heart Failure Therapies - Prices, Progress, and Promise
New informative Journal of Cardiac Failure Ignite π₯by leaders Andrew Oseran, MD MBA & Rishi Wadhera, MD MPP
onlinejcf.com/article/S1071-β¦
Renal Compression in Heart Failure: The Renal Tamponade Hypothesis
The rigidness of the renal capsule is central in congestion-induced damage to the renal structures
Renal decapsulation has been shown to be beneficial in animals
jacc.org/doi/10.1016/j.β¦
Steve Greene
#HeartFailure2024
10 messages to remember from HFA 2024
Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure:
Message 5: Semaglutide reduced the risk of MACE and HF composite in HFrEF and HFpEF
Nurse-Led Diuretic Titration via
POC Urinary Sodium Sensor in
ADHF: EASY-HF trial
Significant improvement in natriuresis and diuresis after 48h, without an increased incidence in adverse events
Wilfried Mullens Steve Greene